October 7, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

 

NRG Oncology seeking applications for travel awards for the next NRG Meeting in January 2020


Application Deadline: 10/25/19

 

  Read more

 


AMENDMENTS
BRAIN

RTOG 1114: Amendment 9; Date: August 23, 2019 (posted on NRG website)

 

RTOG 1114: Amendment 10; Date: September 19, 2019 (posted on NRG website)


FORM UPDATES

NRG-DT001: The Pill Diary DL2 has been updated because of an error regarding the required doses. (posted on NRG website)


OTHER PROTOCOL NOTICES

1. BRAIN

RTOG 0834/EORTC-26053-22054 (CATNON): Protocol Clarification Letter dated October 1, 2019 (posted to CTSU)

 

2. CANCER PREVENTION & CONTROL

NRG-CC003: A revised FAQ document, dated September 30, 2019, is posted to CTSU (Case Report Forms tab).

 

3. GYNECOLOGIC

NRG-GY005: CEC Whole Blood Shipping Address memo (posted on  CTSU)


NRG-GY009: Block Submission Reminder memo (posted on CTSU)

 

NRG-GY018: MMR and PD-L1 Kit Ordering (memo posted on CTSU)


Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more

 

4. VTOC TRAINING

The  VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, October 9.

 

 

DRUG SAFETY UPDATES

Safety updates have been issued for the following studies:

 

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

 Atezolimumab 

 NRG-BR004

 NRG-GI004/SWOG-   S1610

 NRG-GY009

 NRG-GY017

 NRG-LU005

 CTSU

 CTSU

 

 CTSU

 NRG

 CTSU

 Pembrolizumab

 NRG-GI002
 NRG-GY016
 NRG-GY018

 NRG-HN003

 CTSU
 CTSU
 CTSU
 NRG

 Trametinib

 GOG-0281

 CTSU

 

 

NRG Oncology seeking applications for travel awards for the next NRG Meeting in January 2020

NRG Oncology, in partnership with the RTOG Foundation, NSABP Foundation, and GOG Foundation, seek to support attendees to the NRG Oncology Semi-annual meeting occurring January 9-11, 2020 at the Marriott Marquis in Houston, TX. Meeting registration will be opening soon!  Applications for travel awards are due by the close of business October 25, 2019 (10/25/2019) and applicants will be notified by November 22, 2019 (11/22/2019) if they have been selected for an award. The travel award application is posted here.

 


NRG Oncology is seeking an experienced Patient Advocate to serve as Chair for its Patient Advocate Committee

This volunteer position provides the selected individual the responsibility of facilitating and guiding the NRG Oncology Patient Advocate Committee (PAC) and program through a process to update its vision and create an action plan to build on its success. Read more

 


The NRG Oncology New Investigator Committee is Accepting Applications

The NRG Oncology New Investigator Committee is now accepting applications for membership. The committee is requesting applications for new investigators who have completed their oncology training within the last 5 years and are interested in NRG Oncology mentorship. The committee application is posted here.

 

 

PSC Accepting Applications for CTN and CRA Committees and Working Groups
The NRG Oncology Protocol Support Committee (PSC) is accepting applications for membership on the Clinical Trial Nurse (CTN) Committee, Clinical Research Associate (CRA) Committee, and PSC Working Groups (Education and Training, Mentorship, Protocol Review, and Quality Control). CTN and CRA members must also be a member of a Working Group. If you are not currently a member of a working group, you may apply at the same time.

 

If you are interested in becoming a member of any of the committees or groups mentioned above, the Application Request forms, including instructions and descriptions, are posted here.

 

Click the link(s) below to download the specific application form and instructions. Each application is posted as Word .doc, Word .docx, and PDF formats. (login required).

CTN Application

CRA Application

PSC Working Group Application

 

 

Applications are to be submitted by Monday, October 21, 2019. Please forward questions to: NRG-PSC@nrgoncology.org

 

 

Columbus Day Holiday Closures
The NRG Oncology Philadelphia East Operations Center and the SDMC office in Buffalo will be closed on Monday, October 14, 2019 in observance of Columbus Day.

 

Call for Research Proposals
The NRG Oncology Colorectal Cancer subcommittee is seeking vendors and researchers with ctDNA expertise in the field. An RFA for the randomized phase II/III colorectal prospective clinical trial, NRG-CR1902 is posted here. We are seeking a biomarker assay partner to perform CLIA-certified assay testing of patients to detect ctDNA from plasma samples at the time of enrollment and at end of completion of planned adjuvant therapy.  Responses to the RFA due no later than Friday, November 1, 2019. Please direct responses and any questions to Chet Cornman at chet.cornman@nsapb.org.

 

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated  Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 Oct;14(10):1853-1859. doi: 10.1016/j.jtho.2019.06.027. Epub 2019 Jul 11. PubMed PMID: 31302234; PubMed Central PMCID: PMC6764876.   Read More

Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 Sep 17. pii: S0167-8140(19)33066-X. doi: 10.1016/j.radonc.2019.08.020. [Epub ahead of print] PubMed PMID: 31540746.  Read More

Men K, Geng H, Zhong H, Fan Y, Lin A, Xiao Y. A Deep Learning Model for Predicting Xerostomia Due to Radiation Therapy for Head and Neck Squamous Cell Carcinoma in the RTOG 0522 Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):440-447. doi: 10.1016/j.ijrobp.2019.06.009. Epub 2019 Jun 13. PubMed PMID: 31201897; PubMed Central PMCID: PMC6732004.  Read More

Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R,Winter KA, Konski AA, Ajani JA, Bosset JF, Hannoun-Levi JM, Puyraveau M, Chakravarthy AB, Meadows H, Northover J, Collette L, Christiaens M, Maingon P. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019 Sep 28;121:130-143. doi: 10.1016/j.ejca.2019.08.022. [Epub ahead of print] Review. PubMed PMID: 31574418.  Read More

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC,  Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794. [Epub ahead of print] PubMed PMID: 31566680.  Read More

Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A,  Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andr√© T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208. PubMed PMID: 31268130.  Read More



PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

European Society of Gynaecological Oncology (ESGO) Biennial Nov 2-5, 2019; Athens, Greece

 

International Society for Quality of Life Research (ISOQOL); Oct 20-23, 2019; San Diego, CA

 

Society for Neuro-Oncology (SNO); Nov 20-24, 2019; Phoenix, AZ


Upcoming Abstract Submission Deadlines

American Association for Thoracic Surgery (AATS); Apr 25-28, 2020; New York, NY; meeting submission deadline Oct 15, 2019

 

American Head & Neck Society (AHNS); Jul 18-22, 2020; Chicago, IL; due to publications committee Nov 22, 2019; meeting submission deadline Dec 6, 2019

 

American Society of Clinical Oncology (ASCO) GU; Feb 13-15, 2020; San Francisco, CA; due to publications committee Oct 8, 2019; meeting submission deadline Oct 22, 2019

 

American Society of Colon and Rectal Surgeons (ASCRS); Jun 6-10, 2020; Boston, MA; due to publications committee Nov 18, 2019; meeting submission deadline Dec 2, 2019

 

European Society for Radiotherapy and Oncology (ESTRO); Apr 3-7, 2020; Vienna, Austria; due to publications committee Oct 9, 2019; meeting submission deadline Oct 23, 2019; Late submission Jan 15, 2020

 

Society of Gynecologic Oncology (SGO); Mar 28-31, 2020; Toronto, ON Canada; submission deadline Intl abstr  11-5-19; LBA 1-7-20

 

Society of Surgical Oncology (SSO); Mar 25-28, 2020; Boston, MA; meeting submission deadline Oct 7, 2019

 

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse